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Several human APOBEC3 deaminases can inhibit
HIV-1 replication in vitro. HIV-1 Vif counteracts this
restriction by targeting APOBEC3 for proteasomal
degradation. HumanAPOBEC3H (A3H) is highly poly-
morphic, with natural variants differing considerably
in anti-HIV-1 activity in vitro. To examine HIV-1 adap-
tation to variation in A3H activity in a natural infection
context, we determined the A3H haplotypes and Vif
sequences from 76 recently infected HIV-1 patients.
We detected A3H-specific Vif changes suggesting
viral adaptation. The patient-derived Vif sequences
were used to engineer viruses that specifically
differed in their ability to counteract A3H. Replication
of these Vif-variant viruses in primary T cells naturally
expressing active or inactive A3H haplotypes
showed that endogenously expressed A3H restricts
HIV-1 replication. Proviral DNA from A3H-restricted
viruses showed high levels of G-to-A mutations in
an A3H-specific GA dinucleotide context. Taken
together, our data validate A3H expressed at endog-
enous levels as a bona fide HIV-1 restriction factor.
INTRODUCTION
The human APOBEC3 family consists of seven distinct members
(A3A–A3H), of which some inhibit HIV-1 replication through both
deaminating viral cDNA during reverse transcription and
lowering overall reverse transcription (reviewed in Albin and Har-
ris, 2010; Malim and Emerman, 2008). HIV efficiently counteracts
APOBEC3-mediated restriction by encoding the viral Vif protein
which targets APOBEC3 proteins for proteasomal degradation
(Marin et al., 2003; Sheehy et al., 2003). APOBEC3 proteins
such as A3B, A3D, A3F, A3G, and A3H can restrict HIV-1 when
overexpressed in cell culture, but their role in controlling HIV dis-
ease outcome remains unclear (Albin and Harris, 2010; Hultquist
et al., 2011; Ooms et al., 2012). Several studies have found asso-
ciations between APOBEC3 proteins and risk of HIV-1 infection
or and HIV/AIDS disease progression. For example, an A3GCell Hostvariant A3G-186R, commonly found in African populations, has
been associated with higher viral loads and accelerated progres-
sion to AIDS (An et al., 2004; Bunupuradah et al., 2012; Reddy
et al., 2010). In addition, a natural deletion of the A3B gene
was associated with increased HIV acquisition (An et al., 2009).
At least seven distinct human A3H haplotypes exist (Harari
et al., 2009; OhAinle et al., 2008; Wang et al., 2011). These vari-
ants differ in protein stability and in anti-HIV activity (Figure 1A).
Notably, A3H haplotypes which encode 15N and 105R, like hap-
lotypes II (A3H hapII), hapV, and hapVII, restrict HIV-1 (Harari
et al., 2009; OhAinle et al., 2008; Tan et al., 2008; Wang et al.,
2011). The allele frequency of active A3H variants is higher in in-
dividuals of African descent, intermediate in European popula-
tions, and low in Asian populations (OhAinle et al., 2008; Wang
et al., 2011). Moreover, A3H is under strong positive selection
(OhAinle et al., 2006; Ortiz et al., 2009), is expressed in CD4+
T cells, and is upregulated by type 1 interferon (Hultquist et al.,
2011; Refsland et al., 2010, Koning et al., 2009). Interestingly,
A3G is efficiently counteracted by most HIV-1 Vif variants (Binka
et al., 2012; Iwabu et al., 2010; Li et al., 2010; Simon et al., 2005),
but A3H is only degraded by some Vif alleles (Binka et al., 2012;
Li et al., 2010; Ooms et al., 2013). We reported previously that
approximately 50% of Vifs obtained from different HIV-1 sub-
types could degrade active A3H, and we mapped this difference
in activity to two key residues at position 39 and 48 in Vif (Binka
et al., 2012; Ooms et al., 2013).
To test the hypothesis that natural A3H variation affects HIV-1
replication and adaptation in vivo, we determined the A3H haplo-
types of 76 HIV-1-infected individuals enrolled in the San Fran-
ciscoOPTIONScohort early after infection. A comparisonof early
Vif sequences obtained from active and inactive A3H carriers
showed that both groups differed at Vif position 39. Furthermuta-
tional analysis, functional testingof patientVif proteins and forced
evolution experiments of Vifmutants, revealed the requirement of
a phenylalanine or a tyrosine at Vif position 39 for efficient A3H
antagonism. Viruses with point mutations at position 39 that spe-
cifically sensitized the virus to A3H could only replicate efficiently
in primary human peripheral blood mononuclear cells (PBMCs)
expressing inactive A3H variants, but not onPBMCs that express
active A3H alleles. The A3H-restricted viruses showed a high
level of G-to-A mutations in an A3H-specific GA dinucleotide
context. We propose that active A3H is an HIV restriction factor,
which may impact viral replication and elicit viral counteractions.& Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc. 411
Figure 1. A3HHaplotypes Affect Viral Loads
and Time to Treatment of HIV-Infected
Patients in the OPTIONS Cohort
(A) At least seven A3H haplotypes are described
that differ at five amino acid positions (Wang et al.,
2011). Only haplotypes I, II, and III are shown. The
combination of both 15N (rs34522862) and 105R
(rs139297) determine anti-HIV activity of a given
A3H variant.
(B) Seventy-six HIV-infected patients from the
OPTIONS cohort at the University of California,
San Francisco, were selected, and amino acid
identity at position 105 was determined by
SNP array (Illumina). Position 15 (rs34522862)
was determined by PCR and sequencing of
genomic DNA.
(C) A3H haplotype frequencies of haplotypes I, II,
and III. Fifty-six patients do not express any active
A3H hapII, and 20 patients express at least one
active A3H hapII.
(D) Viral loads of inactive A3H and active
A3H carriers were analyzed with a LMEmodel SAS
9.2. Inactive A3H carriers have higher viral loads
(+0.49 log10 c/mL HIV RNA, p < 0.0001) (see also
Table S1).
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A3H Haplotypes, Plasma Viremia, and CD4 Cell Counts
in Newly HIV-Infected Patients
We selected 76 treatment-naive newly infected patients from the
OPTIONS cohort at the University of California, San Francisco
(see Table S1 available online) to determine their A3H haplotypes
and corresponding early Vif sequences (Barbour et al., 2004;
Gourraud et al., 2011).
The participants were mostly male (93%) and of Caucasian
ancestry (76%). The patients were enrolled during primary infec-
tion or early infection (Table S1). Plasma viral loads and CD4+
T cells were recorded regularly during the multiple-year follow-
up. The single nucleotide polymorphism (SNP) at position 105
in A3H (rs139297) was previously determined using a SNP array
assay system (Gourraud et al., 2011).
Twenty-three out of seventy-six patientswere homozygous for
A3H SNP 105G and thus carried two copies of inactive A3H hapI
(Figure 1B). Since the three-nucleotide deletion resulting in the
deletion of 15N (rs34522862), which counteracts the positive
effect of 105R, was not covered by the SNP array used in the pre-
vious study (Gourraud et al., 2011), we amplified and rese-
quenced the N-terminal region of A3H of the remaining 53
patients. Only the combined information regarding A3H residue
position 15 and 105 allows for accurate calling active and inac-
tive A3H haplotypes in each patient (Figure 1B). We grouped
the patients into two groups based on the absence of any active
A3H (N = 56) or the presence of at least one active A3H (N = 20).
Only 2/76 patients were homozygous for A3H hapII (Figure 1C).412 Cell Host & Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc.Of note, the two groups were comparable
regarding age, gender, and ancestry
(Table S1).
A comparison of plasma viral loads
over the first 1,000 days upon enrollmentin patients not receiving HAART was performed with a longitudi-
nal mixed effects model (LME). The mixed-effects model
assesses all viral load data for each patient over time prior to
treatment. It also provides a precise estimate of the viral load
set point for each patient (Gourraud et al., 2011). Modeling re-
sults demonstrated that inactive A3H carriers had higher viral
loads (LME +0.49 log10 c/mL HIV RNA, p < 0.0001) than patients
carrying at least one active A3H copy (Figure 1D). Similarly, an
analysis of CD4+ T cells over time showed a lower CD4+ count
for the inactive A3H carriers (72 CD4+ T cells/ul, SE 20.6, p =
0.0006, data not shown).
Active A3H haplotypes are more frequent in African popula-
tions (OhAinle et al., 2008; Wang et al., 2011), and indeed, three
of the five African Americans enrolled in the cohort carried one or
two active A3H variants. To avoid potential bias caused by
ethnicity, we excluded the five African American participants
from the association analysis. This analysis in which African
American study participants were censored showed a similar dif-
ference in viral load between active and inactive A3H carriers
(+0.4375 log10 c/mL HIV RNA, p < 0.0001, data not shown).
Many patients enrolled in the cohort early upon infection prior
to reaching a viral set point and continued resolution of acute
infection also may contribute to the observed drop in viremia.
In addition, patients with higher plasma viremia initiated antire-
troviral treatment and were subsequently excluded from the
analysis. Nonetheless, in this small cohort, newly infected
patients with active A3H hapII displayed lower viremia and higher
CD4 counts, suggesting that A3Hmay shape viral replication and
adaptation.
Figure 2. Vif Adaption to Active A3H
(A) Vif sequences were generated by RT-PCR and bulk sequencing of plasma
viral RNA. Vif amino acid sequences of active and inactive A3H carriers were
compared with VESPA (Rose and Korber, 2000), and the amino acid frequency
ratios are plotted along the entire Vif sequence. Amino acid identities that differ
more than the threshold are depicted using VisSPA software.
(B) The indicated amino acids were cloned into LAI molecular clone (gray bars),
and the WT LAI amino acids are shown as black bars. WT and mutants LAI
plasmids were cotransfected with an active A3H hapII expression plasmid,
and infectivity of produced viruseswas tested on TZM-bl reporter cells. LAIWT
without A3H hapII and LAI DVif with A3H hapII serve as negative and positive
controls, respectively. Error bars represent standard deviations of three in-
dependent experiments.
(C) LAI WT, DVif, and Vif 39V were cotransfected with all seven human
APOBEC3 members. Infectivity of produced viruses was tested on TZM-bl
reporter cells. Error bars represent standard deviations of three independent
experiments (see also Figure S1).
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Given that not every circulating HIV strain encodes a Vif that
counteracts active A3H (Binka et al., 2012) and not every patient
expresses an active A3H, we hypothesized that Vif adapts to the
presence of an active A3H.
We used early Vif sequences from all 76 patients (2–4 months
after enrollment in the cohort; Figure S1; Gourraud et al., 2011) to
probe for viral adaptation to specific A3H haplotypes. We com-
pard the Vif protein sequences from patients expressing inactive
A3H hapI and hapIII with the Vif protein sequences from patients
harboring at least one copy of active A3H hapII. These two
groups of sequences were compared using VESPA software,
which calculates the frequencies of the most frequent amino
acid at each position of two alignment sets (Korber and Myers,
1992). Figure 2A shows the difference in ratio of the most com-
mon amino acid found at each Vif position. Seven distinct Vif
positions were above a ratio difference, which we arbitrarily set
to 1.4. The amino acid identities at these positions are shown
as WebLogo plots (VisSPA software). Notably, phenylalanineCell Host(F) at position 39 showed the largest difference between the
two groups (60% in active A3H carriers versus 32% in inactive
A3H carriers; Figure 2A).
The different amino acids at the selected seven positions (33,
39, 63, 117, 128, 151, and 167) were introduced into the wild-
type LAI full-length molecular clone and tested for infectivity in
the presence of active A3H hapII (Figure 2B). Mutating Vif posi-
tion 39 to valine completely abrogated its ability to counteract
A3H hapII restriction, while mutating position 63 reduced the
activity of Vif to counteract A3H by 2-fold. The other eight substi-
tutions did not affect the anti-A3H activity of Vif (Figure 2B).
To determine whether the 39V Vif mutant that lost activity
against A3H hapII maintained activity against the other
APOBEC3 proteins, we compared its infectivity to LAI WT and
LAI DVif in the presence of A3A, A3B, A3C, A3D, A3F, A3G,
A3H hapI, and A3H hapII. Figure 2C shows that LAI DVif is
restricted by A3B, A3F, A3G, and A3H hapII, while LAIWT Vif effi-
ciently counteracts A3F, A3G, and A3H hapII. LAI Vif 39V is
defective in counteracting A3H hapII but efficiently neutralizes
A3F and A3G to levels comparable to LAI WT, indicating that
39V only specifically affects anti-A3H function. Of note, A3B is
resistant to both LAI WT and LAI 39V, while A3D has only limited
activity (Figure 2C).
We next addressed the question of whether other natural res-
idues at position 39 in Vif would affect counteracting A3H hapII.
We mutated 39F in LAI WT to the 11 different residues present in
the viruses of the study participants (amino acids C, E, G, H, I, K,
L, S, T, V, and Y). Only LAI WT Vif 39F and LAI Vif mutant 39Y
counteracted A3H hapII efficiently, whereas all the other mutants
were inactive against this protein (Figures 3A and 3B). Of note, all
the Vif 39 mutants were well expressed and degraded A3G effi-
ciently (Figure 3B; data not shown). Phenylalanine (F) and tyro-
sine (Y) both have similar characteristics, suggesting that aro-
matic amino acids at position 39 are required to counteract A3H.
To further analyze the importance of position 39 in counteract-
ing A3H hapII in the context of patient-derived Vifs, we cloned
ten vif variants of available cohort patient samples (see Fig-
ure S1). Three of the patient derived Vif variants encoded 39F,
while the other seven Vifs had a valine (5), methionine (1), or
leucine (1) at this position.
HIV DVif was potently restricted in the absence of A3H hapII,
but all three patient-derived Vif alleles encoding 39F could
rescue infectivity, whereas the other seven Vif 39 variants were
defective in counteracting A3H (Figure 3C). Of note, the differ-
ences in Vif expression levels did not explain the differences in
anti-A3H activity (Figure 3D; e.g., active Vif in lane 1 is well ex-
pressed, whereas the active Vif in lane 3 is poorly expressed).
In summary, viruses from patients with active A3H variants are
more likely to have a F or Y at Vif position 39; residues which
determine selective activity against A3H hapII (12/20 [60%]
39F/Y in active A3H versus 19/56 [34%] 39F/Y in inactive A3H
carriers, p = 0.04, chi-square test; Figures 2A and S1).
Attenuated Fitness of Viruses with A3H-Specific Vif
Defects in T Cell Lines
To further test the APOBEC3 specificity of the Vif 39 mutants, we
conducted spreading infection experiments in permissive MT4
(no APOBEC3 expression) and nonpermissive MT2 (express
APOBEC3) T cells lines. All the LAI Vif 39 variants, except 39G,& Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc. 413
Figure 3. A3H Counteraction of A3H Posi-
tion 39 Variants and Patient Vifs
(A) Different amino acids present at Vif position 39
in the OPTIONS cohort were cloned into LAI. WT
and mutant Vif clones were cotransfected with
A3H hapII. LAI WT 39F is indicated by black bars.
Infectivity of produced viruses was tested on
TZM-bl reporter cells. Error bars represent stan-
dard deviations of three experiments.
(B) 293T cell lysates were analyzed bywestern blot
and probed for HA, Vif, and tubulin.
(C) Ten vif sequenceswere amplified fromdifferent
cohort samples and tested for activity to
counteract A3H hapII and rescue HIV infectivity. The amino acids at position 39, the patient numbers, and the patients’ A3H haplotypes are indicated. Error bars
represent standard deviations of three experiments.
(D) 293T cell lysates were analyzed by western blot and probed for HA, Vif, and tubulin.
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that the mutations did not affect viral replication (Figure 4A).
Nonpermissive MT2 cells do express APOBEC3 proteins, but
the expressed A3H variants are inactive (A3H hapI and A3H ha-
pIII). InMT2 cells, LAIWT and Vif mutants 39V, 39I, 39E, 39Y, and
39H replicated efficiently to similar levels, whereas LAI Vif mu-
tants 39C, 39G, 39T, 39K, 39L, and 39S showed a 5- to 10-
fold reduction in replication (Figure 4A). This replication defect
likely reflects the reduced efficiency in degrading APOBEC3s
other than A3H (e.g., A3D and A3F). Thus, the Vif mutants 39V,
39I, 39E, 39Y, and 39H counteract APOBEC3 (e.g., A3G, A3F)
as efficiently asWT (39F), despite having differential A3H activity.
We selected LAI WT-39F and 39Y that efficiently counteract
A3H hapII, and 39V and 39I which lack activity to counteract A3H
for our next experiments. Of note, WT LAI and the three Vif 39
mutants replicate efficiently on permissive MT4 and nonpermis-
sive MT2 cells (Figure 4A). To test the specific replication effi-
ciency of these four viruses in the presence of only A3G or only
A3H hapII, we infected SupT1 cells transduced with empty,
A3G, or A3H hapII expression plasmids (Figure 4B; Hultquist
et al., 2011). The four viruses replicated similarly on both empty
vector-transduced and A3G-expressing SupT1 cells, confirming
our previous observations that Vif mutants 39Y, 39V, and 39I can
efficiently counteract A3G. In contrast, LAI Vif 39V and 39I
mutants, which were unable to counteract A3H hapII in single-
cycle infectivity assays (Figure 3A), also failed to replicate in
A3H hapII-expressing cells (Figure 4B).
We next tested whether A3H-defective viruses could be
forced to adapt to replicate on SupT1 T cells expressing A3H
hapII. Three independent A3H hapII-expressing SupT1 T cell cul-
tures were infected with three A3H-defective viruses (39I, 39V,
and 39E, nine cultures total), and cells were maintained over a
2-month period. Viral breakthrough was defined by the appear-
ance of syncytia and cell death. Cell-free supernatants collected
at the time of peak breakthrough were used to infect TZM-bl
cells, and proviral vif was amplified and sequenced.
Viral replication was observed in one out of three 39I infections
and in three out of three 39V cultures, whereas no viral break-
through was detected for 39E infections (Figure 4C). Sequencing
of the proviral vifs revealed that in all cases the A3H-resistant
breakthrough virus encoded 39F and with no additional changes
being observed. Interestingly, 39I and 39V only require one
nucleotide change to encode 39F, but 39E, which never adapted
to the presence of active A3H, requires three nucleotide414 Cell Host & Microbe 14, 411–421, October 16, 2013 ª2013 Elsevchanges. Overall, our data underscore the requirement of Vif
39F for specifically counteracting A3H.
Attenuated Fitness of Viruses with A3H-Specific Vif
Defects in Primary Human PBMCs
Because the selected LAI Vif subpanel is highly specific for coun-
teracting active A3H, we next used these viruses to address the
question of whether endogenous expressed A3H restricts viral
replication in primary human lymphocytes. We selected three
donors, which are homozygous for the inactive A3H hapI (donors
1, 2, and 3) and two donors which are homozygous for the active
A3H hapII (donors 4 and 5). Activated PBMCs from all five donors
were infected in duplicates at low multiplicities of infection
(mois), and viral replication was monitored over 19 days. The
four viruses replicated similarly on PBMCs expressing inactive
A3H hapI (Figure 5, donors 1–3). However, when compared to
LAIWT and 39Y, the 39V and 39I viruses, which fail to counteract
A3H, showed a clear replication defect in PBMCs expressing
active A3H hapII (Figure 5). Analyses of the Vif sequences at
the end of the infection (day 19) showed that in all 20 infections
the viruses still retained their original 39 mutations in Vif (data
not shown). These results strongly suggest that endogenous
A3H hapII restricts HIV-1 strains with selective A3H defects.
Endogenously Expressed A3H in Primary Cells
Hypermutates HIV-1
Mutagenesis is a hallmark of APOBEC3 cytidine deaminase
activity (Harris et al., 2003; Mangeat et al., 2003; Zhang et al.,
2003). APOBEC3-induced G-to-A mutations are found more
often in integrated proviruses than in replicating virus (Russell
et al., 2009). We used 454 deep sequencing to analyze the de-
gree and dinucleotide context of mutations accumulated in the
proviruses after 2 weeks of replication (four viruses, five donor
PBMCs, 20 infections). A 335-nt-long region (excluding primers)
was selected in the HIV-1 pol region using highly optimized
primer pairs to avoid any APOBEC3 targets being present in
the primer binding sites (Figures S2A–S2E). PCR fragments rep-
resenting each virus in all five donors were multiplexed and
sequenced in a single run on a 454 Junior sequencer. Addition-
ally, an expression plasmid for full-length HIV-1 LAI was used as
a PCR template to control for 454 sequencing errors. For each
sample, between 3,313 and 9,440 sequences were aligned
and analyzed with Hypermut software (Rose and Korber,
2000). The results are shown as black horizontal linesier Inc.
Figure 4. A3H-Specific Vif Mutant HIV Replication in T Cell Lines
(A) 293T-produced LAIWT and 11 Vif 39mutant viruseswere used to infect permissiveMT4 T cells (no APOBEC3 expression) and permissiveMT2 T cells (express all
APOBEC3membersand inactiveA3HhapIandhapIII).Clarifiedsupernatantswereharvestedevery2days, and infectivitywasdeterminedbyaTZM-bl infectivityassay.
(B) SupT1 cell lines transduced with empty, A3G, or A3H hapII expression plasmids (Hultquist et al., 2011) were infected with LAI WT 39F, 39V, 39I, and 39Y, and
supernatants were harvested each day and tested for infectivity using a TZM-bl infectivity assay.
(C) A3H hapII-expressing SupT1 T cells were infected in triplicate with three viruses encoding A3H-defective Vifs (39I, 39V, and 39E; each codon is indicated).
Cultures weremaintained until the appearance of syncytia and cell death (days of breakthrough are indicated with circled numbers). Vifswere sequenced, and the
resulting Vif adaptations are indicated.
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dashes indicate APOBEC3 specific G-to-A mutations (Figure 6).
The data panels of the 39V and 39I viruses on active A3H hapII-
expressing cells showed an increase in G-to-A mutations in an
A3H preferred GA dinucleotide context (blue dashes, Figure 6;
Harari et al., 2009). All the other data panels show low levels of
red and blue dashes, representing A3G-specific GG-to-AG
mutations (red) and GA-to-AA mutations possibly generated by
A3D or A3F (no active A3H is present; Refsland et al., 2012).
Quantitative Analysis of APOBEC3-InducedMutations in
Primary Cells
Next, we quantitatively analyzed the 454 deep-sequencing data
by calculating the frequency of each mutation present in each
unique sequence. The majority of mutations detected were
G-to-A mutations in dinucleotide contexts, suggestive of
APOBEC3 action (indicated in gray, Figure 7A). The proviral
sequences from the A3H hapII-expressing PBMCs (donors 4
and 5) infectedwith A3H-defective Vif mutants (Vif 39V/I) showed
four times more G-to-A mutations for each unique sequence
compared to the other infections (Figure 7A, p < 0.001). A small
number of other mutations were observed, which was similar to
the plasmid vector control, likely representing 454 sequencing
errors. The G-to-A mutations were further subdivided into theCell Hostfour different dinucleotide contexts, which showed a significant
increase of GA-to-AA mutations per individual sequence for
the A3H-restricted, A3H-defective Vif mutants (Vif 39V/I)
compared to the nonrestricted viruses (indicated in blue, Fig-
ure 7B; p < 0.001, unpaired t test). The other sequences
contained a similar low level of GG-to-AG (A3G-specific) and
GA-to-AA mutations (Figure S3; Refsland et al., 2012). The
A3H-defective viruses 39V and 39I on active A3H-expressing
PBMCs also showed an increased level in the number of A3H-
specific GA-to-AA mutations per sequence and in their respec-
tive frequencies, whereas the other samples showed a lower
number per sequence and their frequencies of both GG-to-AG
and GA-to-AA mutations (Figure 7C).
Overall, more A3H-specific mutations were observed upon
infection of PBMCs expressing active A3H with A3H-neutraliza-
tion defective viruses Vif 39V and 39I, indicating that endoge-
nously expressed A3H hapII mutates proviral DNA when not
counteracted by Vif.
DISCUSSION
Human A3H variants are the only APOBEC3 proteins that differ
greatly in anti-HIV activity, but their antiviral activity has only
been demonstrated in overexpression experiments. In this study& Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc. 415
Figure 5. A3H-Specific Vif Mutant HIV Replication in PBMCs
PBMCs from five anonymous donors (three homozygous for A3H hapI, donors 1–3; and two homozygous for A3H hapII, donors 4 and 5) were infected with the
indicated viruses. Clarified supernatants were harvested every 2 days, and infectivity was determined by a TZM-bl infectivity assay. Error bars represent standard
deviations of two independent infections.
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derived from patients with and without active A3H haplotypes.
The patient-derived Vif information revealed the importance of
Vif position 39, which is required for specifically antagonizing
A3H in single- and multiple-round infection experiments (Figures
3 and 4), Importantly, viruses unable to counteract A3H showed
reduced replication and increased A3H-specific mutagenesis
only on primary cells that naturally express active A3H (Figure 5).
We observed that active A3H carriers more often harbor an
HIV-1 capable of efficiently counteracting A3H, indicating that
HIV may adapt to the presence of an active A3H. We speculate
that when an A3H-sensitive HIV strain infects an individual
expressing active A3H, the virus would initially be restricted
but over time would adapt to become A3H resistant. In contrast,
when a newly infected person only expresses inactive A3H
variants, HIV would replicate efficiently regardless of its anti-
A3H activity. Importantly, this potential effect of active A3H on
HIV-1 replication and subsequent adaptation in vivo is only
apparent because not every person expresses an active A3H.
If A3H was not polymorphic (e.g., every individual human being
expresses an active A3H similar to A3G), the virus would always
be A3H resistant. The observation that the patient group with
active A3H had lower average viral loads, yet more often yielded416 Cell Host & Microbe 14, 411–421, October 16, 2013 ª2013 ElsevA3H-resistant viruses, seems counterintuitive (Figures 1D and
2A). However, this could be explained by the fact that this group
still comprises a sizable number of individuals that carry viruses
that are not yet adapted to A3H (40%, Figure 2A).
Although the patient-derived Vif information correctly
pinpointed A3H-specific Vif adaptation, a number of important
limitations of our cohort population need to be noted. First the
number of patients encoding at least one active A3H is limited
(N = 20) in this cohort of 76 newly infected patients. Few individ-
uals could contribute a disproportionate number of data and
thereby confound the analysis in such small study populations.
Indeed, many genetic factors associated with HIV progression
in previous studies could not be confirmed in larger cohorts
(McLaren et al., 2013). Therefore, future analyses of other inde-
pendent HIV patient cohorts are required to determine the role
of A3H haplotypes on HIV disease progression and viral adapta-
tion. Importantly, both A3H SNPs rs34522862 (A3H D15) and
rs139297 (A3H 105R) need to be analyzed jointly in order to
correctly assign the A3H activity (Figures 1A and 1B). However,
A3H D15, a 3 nt indel, is not covered by the widely used Illumina
SNP array platforms. Therefore, correctly assigning A3H haplo-
types necessitates customized assays or genome/exome
sequencing.ier Inc.
Figure 6. Endogenously Expressed A3H in
Primary Cells Hypermutates HIV-1
Cellular DNA was extracted from the infected
PBMCs of Figure 5B and used to amplify a 335 bp
fragment in pol (excluding primers). The same
fragment amplified using plasmid DNA served as
a control for 454 induced sequencing errors.
Between 3,313 and 9,440 sequences per sample
were generated. APOBEC3-specific hypermu-
tations in unique sequences were detected with
Hypermut software (Rose and Korber, 2000). The
software-generated results represent a black
horizontal line for each unique sequence and small
colored dashes indicating APOBEC3-specific
G-to-A mutations (see also Figure S2).
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HIV Restriction by Natural APOBEC3H VariantsIn this study we describe the importance of Vif position 39 in
specifically counteracting A3H. However, other Vif residues likely
also play a role, since other residue differences were observed
between active and inactive A3H carriers (Figures 2A and 2B).
In addition, we previously reported the importance of Vif position
48 for A3H degradation (Binka et al., 2012, Ooms et al., 2013).
One can envision a number of reasons why Vif proteins lose
their activity to counteract A3H. First, the lack of selection pres-
sure in the absence of active A3H in combination with viral ge-
netic drift could lead to loss of function. Alternatively, the loss
of anti-A3H activity in the absence of active A3H could result
from minor improvements of A3H-defective Vif to counteract
other APOBEC3 proteins. However, no increased infectivity
was observed for A3H-sensitive viruses in the presence of other
APOBEC3 in our infection assays (Figures 2C, 4A, 4B, and 5).
Lastly, additional Vif functions such as cell-cycle arrest (Izumi
et al., 2010; DeHart et al., 2008) could overlap with the ability
to counteract A3H and favor viral reversions.
Multiple studies have found APOBEC3-induced hypermuta-
tions in HIV-1 sequences derived from cell-culture experiments
as well as from HIV-infected patients (Janini et al., 2001; Lidda-
ment et al., 2004). The dinucleotide preference of A3G and other
APOBEC3 proteins is strikingly different: A3G prefers GG to AG
mutations, while GA to AA is preferred by A3A, A3B, A3C, A3D,
A3F, and A3H (reviewed in Albin and Harris, 2010). Interestingly,
both dinucleotide contexts are observed in patients, indicating
that, next to A3G, other APOBEC3 proteins target HIV (Janini
et al., 2001; Liddament et al., 2004; Vartanian et al., 1991). Our
study shows extensive GA-to-AA mutations in active A3H ha-
pII-expressing primary cells infected with A3H-defective 39V/ICell Host & Microbe 14, 411–421,viruses, indicating that A3H may
contribute to the observed GA-to-AA
mutations in vivo (Figures 6 and 7). In
addition, we also observed lower but
similar levels of G-to-A mutations in
both dinucleotide contexts in proviruses
obtained from infections of primary
PBMCs expressing only inactive A3H.
These observations suggest that both
A3G and APOBEC3 proteins other than
A3H can edit HIV-1 (potentially A3D or
A3F; Refsland et al., 2012).Taken together, our data suggest that A3H could be a bona
fide restriction factor for HIV-1. While our current knowledge of
distinct haplotypes of other APOBEC3 proteins is limited, it is
tempting to speculate that the combination of diverse APOBEC3
repertoires and viruses that are not yet adapted to this variation
could impact HIV pathogenesis.
EXPERIMENTAL PROCEDURES
Study Population
Seventy-six patients were selected from a previous study conducted with
samples from the OPTIONS cohort (Barbour et al., 2004; Gourraud et al.,
2011). All cohort participants provided informed consent that allowed for
the use of their specimen for studies of immunogenetic processes in HIV
disease. Patients were enrolled early postinfection and followed at 4- to
8-week intervals. Plasma viral loads and CD4+ T cell numbers were
documented. Most participants are male (93%), Caucasian (76%), and
infected with HIV-1 subtype B. The majority of patients are MSM (see also
Table S1). SNPs present in the APOBEC3 locus were previously analyzed
by GoldenGate SNP array assay system (Gourraud et al., 2011). Vif pop-
ulation sequences were previously obtained from proviral DNA of PBMCs
taken at early time points (2–4 months) after enrollment (Gourraud et al.,
2011).
A3H SNP 15N Genotyping of OPTIONS Cohort Patients
Genomic DNAwas extracted from patient PBMCs using DNeasy DNA isolation
kit (QIAGEN). A 246 bp fragment spanning the A3H 15N position was amplified
with primers 3H15N3+ 50-GTGGCTTGAGCCTGGGGTGA and A3H15N3- 50-
CAGAGAGCCCGTGTGGCACC using Taq polymerase (QIAGEN) with the
following PCR program settings: 95C for 3 min (initial denaturation) followed
by 35 cycles of 95C for 30 s, 65C for 30 s, and 72C for 30 s and a final elon-
gation step at 72C for 5 min. Column-purified PCR products were sequenced
with the reverse primer A3H15N3.October 16, 2013 ª2013 Elsevier Inc. 417
Figure 7. Quantitative Analysis of APOBEC3-Induced Mutations in Primary Cells
(A) 454 deep sequencing-generated unique sequences were analyzed with Hypermut software (Rose and Korber, 2000), and the results were plotted as number
of mutations per unique sequence. APOBEC3-specific G-to-A mutations are indicated in gray, whereas all other mutations are shown in white. ***p < 0.001
(unpaired t tests, Prism software).
(B) Hypermut software results were plotted only for APOBEC3-specific G-to-A mutations per individual sequence. The specific dinucleotide contexts of each
G-to-A mutation were shown with the indicated colors, with A3G-specific GG to AG in red and GA to AA mutations in blue. ***p < 0.001 (unpaired t tests, Prism
software).
(C) Hypermut results were analyzed and shown as the number of sequences with the indicated number of either GG-to-AG (red) or GA-to-AAmutations (blue) per
individual sequence. The number of sequences without GG-to-AG and GA-to-AA mutations are indicated by gray bars (see also Figure S3).
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The replication-competent HIV molecular clone LAI (Peden et al., 1991) was
obtained from the AIDS Research and Reference Reagent Program. LAI DVif
with a 284 nt deletion in vif was described previously (Ooms et al., 2013). All
LAI Vif mutants were generated by standard overlap PCR mutagenesis using
EcoRI and NdeI sites at positions 4,230 and 5,982, respectively (LAI K02013
numbering). Expression plasmids for C-terminal 3xHA-tagged A3A, A3B,
A3C, A3D, A3F, A3G and A3H hapI; A3H hapII; andGFPwere described before
(Ooms et al., 2012). C-terminal 3xHA-tagged A3H hapIII was generated by
standard overlap PCR mutagenesis.418 Cell Host & Microbe 14, 411–421, October 16, 2013 ª2013 ElsevPatient Vif Cloning
RNA was extracted from available PBMCs samples from ten cohort partici-
pants. cDNA was generated using SuperScript II First Strand Synthesis
System (Invitrogen). Vif was amplified with Vif+ 50-GATCCACTTTGGAAAG
GACCAGCAAAGCT-30 and Vif- 50-ATGGCTTCCACTCCTGCCCAAGTATC-30
using Pfx50 high-fidelity polymerase (Invitrogen). PCR products were cloned
with Strataclone (Stratagene) and sequenced. Individual vif alleles were PCR
amplified from selected clones, C-terminally FLAG tagged using standard
overlap PCR, and subcloned into the PCRV1 Vif expression plasmid as
described (Simon et al., 2005).ier Inc.
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HIV Restriction by Natural APOBEC3H VariantsAssessment of Anti-APOBEC3 Activity of Viruses using Single-Cycle
Infectivity Assays
The 3xHA-tagged APOBEC3 expression vectors (20 ng) were cotransfected
with HIV LAI molecular clones (500 ng) in HEK293T cells. For the Vif-comple-
mentation assay, 500 ng of NL4-3 DVif was cotransfected with 20 ng of A3H
hapII expression plasmid and 50 ng Vif expression plasmids. The transfections
were performed in a 24-well plates using 3 mg/ml polyethylenimine (PEI; Poly-
sciences, Inc.). The culture medium was used to infect TZM-bl reporter cells
48 hr after transfection. TZM-bl infections were performed in duplicates with
20 ml of cell-free viral supernatants in 96-well plates. b-galactosidase activity
was quantified 48 hr after infection using Tropix (Perkin-Elmer).
Cell Culture
Cells were maintained at 37C in a humidified atmosphere of 5% CO2. TZM-bl
cells, MT2 T cells, and MT4 T cells were provided by the AIDS Research and
Reference Reagent Program (Haertle et al., 1988; Harada et al., 1985; Wei
et al., 2002).
The adherent cell lines HEK293T and TZM-bl weremaintained in Dulbecco’s
high-glucose modified Eagle’s medium, supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 50 units/ml penicillin, and 50 mg/ml strepto-
mycin. SupT1-control (empty vector transduced), SupT1-A3G, and SupT1-
A3H hapII were kindly provided by Reuben Harris (Hultquist et al., 2011). All
T cell lines were cultured in Roswell Park Memorial Institute medium 1640
(RPMI 1640) supplemented with 10% FBS, 2 mM glutamine, 50 units/ml peni-
cillin, and 50 mg/ml streptomycin.
Primary human PBMCs were obtained from HIV-1-negative anonymous
donors (Mount Sinai School of Medicine Blood Bank). PBMCs were stimulated
with phytohemagglutinin (PHA, 1 mg/ml) and cultured in RPMI supplemented
with 10% FBS, Pen/Step, 2.3mg/ml HEPES, Glutamine and 20 U/ml inter-
leukin-2 (IL-2) for 48–72 hr.
A3H Genotyping of PBMCs and T Cell Lines
Cellular RNA from human PBMCs and MT2 andMT4 T cell lines was extracted
using QIAGEN RNA extraction kit (Harari et al., 2009). RNA was reverse
transcribed with Superscript II (Invitrogen). A3H cDNA was amplified with
PicoMax DNA polymerase (Stratagene) using primers 50-AACGCTCGG
TTGCCGCCGGGCGTTTTTTATTATGGCTCTGTTAACAG-30 and 50-TCTTG
AGTTGCTTCTTGATAAT-30. PCR products were cloned using a StrataClone
kit (Stratagene). Six to fourteen clones were sequenced for each donor/cell
line.
HIV Replication on T Cell Lines and PBMCs
Viral stocks were produced by transfecting HEK293T cells with 500 ng of
molecular LAI WT molecular clones or the indicated LAI Vif mutants in 24-
well plates using 3 mg/ml polyethylenimine (PEI; Polysciences, Inc.). Superna-
tants were harvested 2 days posttransfection. Infectivity titers of the viral
stocks were determined by infecting TZM-bl reporter cells in triplicate with se-
rial dilutions.
MT2 and MT4 Infections
3 3 105 MT2 and MT4 cells were infected overnight with the WT and three Vif
mutant viral stocks in the presence of 2 mg/ml polybrene in 96-well round-bot-
tom plates. Cells were washed three times and maintained in complete RPMI
for 7 days. Culture supernatants were collected at days 1, 3, 5, and 7 and cryo-
preserved until the infectivity reporter assay was conducted at the end of the
infection.
SupT1 Infection
1.5 3 106 cells of each SupT1 cell line (transduced with control empty vector,
A3G, and A3H hapII expression plasmids) were infected (moi 0.5) in a 24-well
format (1.5 ml) and washed with media 10 hr postinfection. Each day, 200 ml
supernatants were collected, clarified, and stored at 80C, and cultures
were supplemented with fresh media.
SupT1 Evolution Infection
5.03 106 A3H hapII-expressing SupT1 T cells were infected with LAI 39I, 39V,
and 39I (moi 1.0) in individual 25 ml flasks. Cells were maintained by splitting
1:10 or 1:5 twice a week, and supernatants were collected after formation of
syncytia and cell death. 2.0 3 105 TZM-bl cells in a 24-well format were in-
fected with 100 ml supernatants, and cellular DNA was extracted with DNeasy
DNA isolation kit 2 days postinfection (QIAGEN). Vif was amplified with primersCell HostVif+ and Vif using Pfx50 high-fidelity polymerase (Invitrogen). PCR products
were sequenced with the Vif+ primer.
PBMC Infections
3 3 105 PHA stimulated PBMC from five donors was infected overnight with
the four different viral stocks in the presence of 2 mg/ml polybrene in 96-well
round-bottom plates. After infection, cells were washed three times and main-
tained in complete RPMI supplemented with 20 units per ml of IL-2 over
21 days. Culture supernatants were collected every 2–4 days. Experiments
were performed twice with the same five donors.
Assessment of Infectivity using TZM-bl Reporter Cells
The culture supernatants of the T cell lines and PBMCs were used to infect
TZM-bl cells in triplicate (20 ml, 96-well plates), and b-galactosidase activity
was quantified 48 hr after infection using Tropix (Perkin-Elmer), as described
(Harari et al., 2009).
PBMC DNA Extraction, PCR, and 454 Sequencing
Genomic DNA from PBMC was extracted using the DNeasy DNA isolation kit
(QIAGEN). A 508 bp fragment of HIV-1 LAI pol was amplified with primers
Pol-outer+ 2115-GTTGCACTTTAAATTTTCCCATTAGTCCTATT-2146 and
Pol-outer 2622-ATGCTACTTTGGAATATTGCTGGTGA-2597 (LAI K02013
numbering) using Pfx50 high-fidelity polymerase (Invitrogen). The PCRparame-
ters were as follows: 94C for 2 min; 25 cycles with 94C for 30 s, 58C for 15 s,
and 68C for 30 s; followed by 5 min at 68C. A nested 335 bp PCR fragment
(excluding primer targets and 454 tags) was amplified with unique MID-tagged
(Roche) primers Pol-inner+ 454tag-2148-AAACTGTACCAGTAAAATTAA
AGCCA-2173 1955-Pol inner- 454tag-2539-GTTTATACTAGGTATGGTAAATG
CAGTATAC-2509 with PfuUltra II Fusion HotStart DNA Polymerase (Agilent
Technologies). The PCR parameters were as follows: 94C for 2 min; 25 cycles
with 94 for 15 s, 50C for 15 s, and 72C for 20 s; followed by 5min at 72C. Am-
plicons were diluted to 13 109 molecules/mL and pooled. The pooled DNAwas
diluted and added to an emulsion PCR with a GS Junior Titanium emPCR Kit
(Lib-A) kit (Roche), at a concentration of 0.25 copies per bead. This emulsion
PCR kit contains two types of beads to enable sequencing of the target from
both forward and reverse directions. TheemulsionPCRprotocolwasas follows:
4min at 94C, followed by 50 cycles of 30 s at 94C, 4.5min at 58C, and 30 s at
68C. After amplification in emulsion droplets, clonal DNA-coated beads were
purified from the emulsion oil in a series of alcohol washes, and then magnetic
beads were used to enrich DNA-coated beads. DNA beads were prepared for
sequencing on the Roche 454 Genome Sequencer Junior instrument with the
GS Junior Titanium Sequencing kit (Roche), loaded onto a PicoTiter Plate
(Roche), and sequenced in 200 cycles in 10 hr.
454 Deep-Sequencing Analyses
Sequences were exported from the Roche 454 GS Junior workstation, after
amplicon processing, as .fna and .qual files. Both files were processed in
custom code in the SAS System for assignment back to specimen by unique
MID tags combinations in the 50 and 30 end of each sequence. Sequenceswere
screened for sequence lengths and PHRED scores equal or higher than 30.
These high-quality sequences were partitioned into amplicon type by length,
primer, and sequence tags. Sequences were sorted by unique sequence iden-
tity and counted, and one instance of each unique sequence was exported,
along with the 454 unique sequence name, patient ID, MID combination,
average PHRED score, and count of number of instances of that sequence.
Sequences of each sample were aligned using MUSCLE (Edgar, 2004a,
2004b) to the reference HIV LAI K02013, and both primer binding sites were
stripped. The sequences showed a high level of deletions mainly in A-runs,
which likely represent 454 sequence artifacts as they were also present in
the plasmid control. Sequences were manually edited for remaining mis-
aligned sections and handling gaps due to poly(A) runs against the reference
sequence. Aligned sequences were analyzed by Hypermut software (Rose
and Korber, 2000) with the LAI K02013 a reference using standard settings.
The Hypermut data were exported to Microsoft Excel for further analysis.
Statistical Analysis
The analysis of A3H haplotypes, viral loads, and CD4 cell counts was per-
formed with LME models in the SAS System (SAS Institute, Cary, NC, USA)
with Proc Mixed and random effects specified for intercept and time.& Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc. 419
Cell Host & Microbe
HIV Restriction by Natural APOBEC3H VariantsGraphPad Prism 5 Software was used to perform statistical tests (mean,
median, standard deviations, Fisher’s exact test, chi-square test, Mann
Whitney test, and t test). p values are two-sided, and values <0.05 were
considered to be significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one table and can be
found with this article at http://dx.doi.org/10.1016/j.chom.2013.09.006.
ACKNOWLEDGMENTS
We thank the participants of the OPTIONS Cohort at San Francisco General
Hospital. We thank Dr. Reuben Harris for the SupT1 T-cell lines expressing
empty vector, A3G, and A3H hapII. This work was funded in part by NIH/NIAID
grants R01 AI089246 and AI064001 (V.S.), by K01 AI 066917 (J.D.B.), by P01
AI071713 (F.M.H.), by a Public Health Service Institutional Research Training
Award T32A107647 (M.L.), and by the University of California, San Francisco,
Academic Senate Individual Investigators Research Grant (J.D.B.).
Received: May 29, 2013
Revised: August 2, 2013
Accepted: August 30, 2013
Published: October 16, 2013
REFERENCES
Albin, J.S., and Harris, R.S. (2010). Interactions of host APOBEC3 restriction
factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol.
Med. 12, e4.
An, P., Bleiber, G., Duggal, P., Nelson, G., May, M., Mangeat, B., Alobwede, I.,
Trono, D., Vlahov, D., Donfield, S., et al. (2004). APOBEC3G genetic variants
and their influence on the progression to AIDS. J. Virol. 78, 11070–11076.
An, P., Johnson, R., Phair, J., Kirk, G.D., Yu, X.F., Donfield, S., Buchbinder, S.,
Goedert, J.J., and Winkler, C.A. (2009). APOBEC3B deletion and risk of HIV-1
acquisition. J. Infect. Dis. 200, 1054–1058.
Barbour, J.D., Hecht, F.M., Wrin, T., Segal, M.R., Ramstead, C.A., Liegler, T.J.,
Busch, M.P., Petropoulos, C.J., Hellmann, N.S., Kahn, J.O., and Grant, R.M.
(2004). Higher CD4+ T cell counts associated with low viral pol replication
capacity among treatment-naive adults in early HIV-1 infection. J. Infect.
Dis. 190, 251–256.
Binka, M., Ooms, M., Steward, M., and Simon, V. (2012). The activity spectrum
of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and
APOBEC3H. J. Virol. 86, 49–59.
Bunupuradah, T., Imahashi, M., Iampornsin, T., Matsuoka, K., Iwatani, Y.,
Puthanakit, T., Ananworanich, J., Sophonphan, J., Mahanontharit, A., Naoe,
T., et al.; PREDICT Study Team. (2012). Association of APOBEC3G genotypes
and CD4 decline in Thai and Cambodian HIV-infected children with moderate
immune deficiency. AIDS Res. Ther. 9, 34.
DeHart, J.L., Bosque, A., Harris, R.S., and Planelles, V. (2008). Human immu-
nodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the
same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degrada-
tion. J. Virol. 82, 9265–9272.
Edgar, R.C. (2004a). MUSCLE: a multiple sequence alignment method with
reduced time and space complexity. BMC Bioinformatics 5, 113.
Edgar, R.C. (2004b). MUSCLE: multiple sequence alignment with high accu-
racy and high throughput. Nucleic Acids Res. 32, 1792–1797.
Gourraud, P.A., Karaouni, A., Woo, J.M., Schmidt, T., Oksenberg, J.R., Hecht,
F.M., Liegler, T.J., and Barbour, J.D. (2011). APOBEC3H haplotypes andHIV-1
pro-viral vif DNA sequence diversity in early untreated human immunodefi-
ciency virus-1 infection. Hum. Immunol. 72, 207–212.
Haertle, T., Carrera, C.J., Wasson, D.B., Sowers, L.C., Richman, D.D., and
Carson, D.A. (1988). Metabolism and anti-human immunodeficiency virus-1
activity of 2-halo-20,30-dideoxyadenosine derivatives. J. Biol. Chem. 263,
5870–5875.420 Cell Host & Microbe 14, 411–421, October 16, 2013 ª2013 ElsevHarada, S., Koyanagi, Y., and Yamamoto, N. (1985). Infection of human T-lym-
photropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus):
chronological studies of early events. Virology 146, 272–281.
Harari, A., Ooms, M., Mulder, L.C., and Simon, V. (2009). Polymorphisms and
splice variants influence the antiretroviral activity of human APOBEC3H.
J. Virol. 83, 295–303.
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K.,
Watt, I.N., Neuberger, M.S., and Malim, M.H. (2003). DNA deamination medi-
ates innate immunity to retroviral infection. Cell 113, 803–809.
Hultquist, J.F., Lengyel, J.A., Refsland, E.W., Larue, R.S., Lackey, L., Brown,
W.L., and Harris, R.S. (2011). Human and rhesus APOBEC3D, APOBEC3F,
APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict
Vif-deficient HIV-1. J. Virol. 85, 11220–11234.
Iwabu, Y., Kinomoto, M., Tatsumi, M., Fujita, H., Shimura, M., Tanaka, Y.,
Ishizaka, Y., Nolan, D., Mallal, S., Sata, T., and Tokunaga, K. (2010).
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different
subtypes. J. Biol. Chem. 285, 35350–35358.
Izumi, T., Io, K., Matsui, M., Shirakawa, K., Shinohara, M., Nagai, Y.,
Kawahara, M., Kobayashi, M., Kondoh, H., Misawa, N., et al. (2010). HIV-1 viral
infectivity factor interacts with TP53 to induce G2 cell cycle arrest and posi-
tively regulate viral replication. Proc. Natl. Acad. Sci. USA 107, 20798–20803.
Janini, M., Rogers, M., Birx, D.R., and McCutchan, F.E. (2001). Human immu-
nodeficiency virus type 1 DNA sequences genetically damaged by hypermuta-
tion are often abundant in patient peripheral blood mononuclear cells and may
be generated during near-simultaneous infection and activation of CD4(+)
T cells. J. Virol. 75, 7973–7986.
Koning, F.A., Newman, E.N., Kim, E.Y., Kunstman, K.J., Wolinsky, S.M., and
Malim, M.H. (2009). Defining APOBEC3 expression patterns in human tissues
and hematopoietic cell subsets. J. Virol. 83, 9474–9485.
Korber, B., and Myers, G. (1992). Signature pattern analysis: a method for
assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8,
1549–1560.
Li, M.M., Wu, L.I., and Emerman, M. (2010). The range of human APOBEC3H
sensitivity to lentiviral Vif proteins. J. Virol. 84, 88–95.
Liddament, M.T., Brown, W.L., Schumacher, A.J., and Harris, R.S. (2004).
APOBEC3F properties and hypermutation preferences indicate activity
against HIV-1 in vivo. Curr. Biol. 14, 1385–1391.
Malim, M.H., and Emerman, M. (2008). HIV-1 accessory proteins—ensuring
viral survival in a hostile environment. Cell Host Microbe 3, 388–398.
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003).
Broad antiretroviral defence by human APOBEC3G through lethal editing of
nascent reverse transcripts. Nature 424, 99–103.
Marin, M., Rose, K.M., Kozak, S.L., and Kabat, D. (2003). HIV-1 Vif protein
binds the editing enzyme APOBEC3G and induces its degradation. Nat.
Med. 9, 1398–1403.
McLaren, P.J., Coulonges, C., Ripke, S., van den Berg, L., Buchbinder, S.,
Carrington, M., Cossarizza, A., Dalmau, J., Deeks, S.G., Delaneau, O., et al.
(2013). Association study of common genetic variants and HIV-1 acquisition
in 6,300 infected cases and 7,200 controls. PLoS Pathog. 9, e1003515.
OhAinle, M., Kerns, J.A., Malik, H.S., and Emerman, M. (2006). Adaptive
evolution and antiviral activity of the conserved mammalian cytidine deami-
nase APOBEC3H. J. Virol. 80, 3853–3862.
OhAinle, M., Kerns, J.A., Li, M.M., Malik, H.S., and Emerman, M. (2008).
Antiretroelement activity of APOBEC3H was lost twice in recent human evolu-
tion. Cell Host Microbe 4, 249–259.
Ooms, M., Krikoni, A., Kress, A.K., Simon, V., and Mu¨nk, C. (2012).
APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lym-
photropic virus type 1. J. Virol. 86, 6097–6108.
Ooms,M., Letko, M., Binka, M., and Simon, V. (2013). The resistance of human
APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino
acid in Vif. PLoS ONE 8, e57744.
Ortiz, M., Guex, N., Patin, E., Martin, O., Xenarios, I., Ciuffi, A., Quintana-Murci,
L., and Telenti, A. (2009). Evolutionary trajectories of primate genes involved in
HIV pathogenesis. Mol. Biol. Evol. 26, 2865–2875.ier Inc.
Cell Host & Microbe
HIV Restriction by Natural APOBEC3H VariantsPeden, K., Emerman, M., and Montagnier, L. (1991). Changes in growth prop-
erties on passage in tissue culture of viruses derived from infectious molecular
clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185, 661–672.
Reddy, K., Winkler, C.A., Werner, L., Mlisana, K., Abdool Karim, S.S., and
Ndung’u, T.; CAPRISA Acute Infection Study Team. (2010). APOBEC3G
expression is dysregulated in primary HIV-1 infection and polymorphic variants
influence CD4+ T-cell counts and plasma viral load. AIDS 24, 195–204.
Refsland, E.W., Stenglein, M.D., Shindo, K., Albin, J.S., Brown, W.L., and
Harris, R.S. (2010). Quantitative profiling of the full APOBEC3mRNA repertoire
in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids
Res. 38, 4274–4284.
Refsland, E.W., Hultquist, J.F., and Harris, R.S. (2012). Endogenous origins of
HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line
CEM2n. PLoS Pathog. 8, e1002800.
Rose, P.P., and Korber, B.T. (2000). Detecting hypermutations in viral
sequences with an emphasis on G / A hypermutation. Bioinformatics 16,
400–401.
Russell, R.A., Moore, M.D., Hu, W.S., and Pathak, V.K. (2009). APOBEC3G
induces a hypermutation gradient: purifying selection at multiple steps during
HIV-1 replication results in levels of G-to-A mutations that are high in DNA,
intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6, 16.Cell HostSheehy, A.M., Gaddis, N.C., andMalim, M.H. (2003). The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat.
Med. 9, 1404–1407.
Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D.D., and Bieniasz, P.D.
(2005). Natural variation in Vif: differential impact on APOBEC3G/3F and a
potential role in HIV-1 diversification. PLoS Pathog. 1, e6.
Tan, L., Sarkis, P.T.N., Wang, T., Tian, C., and Yu, X.-F. (2008). Sole copy of
Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against
retrotransposons and HIV-1. FASEB J. 23, 279–287.
Vartanian, J.P., Meyerhans, A., Asjo¨, B., and Wain-Hobson, S. (1991).
Selection, recombination, and G——A hypermutation of human immunodefi-
ciency virus type 1 genomes. J. Virol. 65, 1779–1788.
Wang, X., Abudu, A., Son, S., Dang, Y., Venta, P.J., and Zheng, Y.H. (2011).
Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency
virus type 1 activity. J. Virol. 85, 3142–3152.
Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag, M.S.,
Wu, X., Shaw, G.M., and Kappes, J.C. (2002). Emergence of resistant human
immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)
monotherapy. Antimicrob. Agents Chemother. 46, 1896–1905.
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C., and Gao,
L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly
synthesized HIV-1 DNA. Nature 424, 94–98.& Microbe 14, 411–421, October 16, 2013 ª2013 Elsevier Inc. 421
